Mechanism for increased immunogenicity of vaccines that form in vivo immune complexes with the natural anti-Gal antibody

Vaccine

Volumn 27, Issue 23, 2009, Pages 3072-3082

  Abdel Motal, Ussama M ^a   Wigglesworth, Kim ^a   Galili, Uri ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Gal glycolipids; Anti Gal antibody; APC; Vaccine

Indexed keywords

ALPHA 1,3 GALACTOSYLTRANSFERASE; ANTIBODY; APC; FC RECEPTOR; GAL ANTIBODY; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G; INFLUENZA VACCINE; LIPOSOME; UNCLASSIFIED DRUG; VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IN VIVO STUDY; LYMPH NODE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; T LYMPHOCYTE ACTIVATION; VACCINATION;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGEN-ANTIBODY COMPLEX; BACTERIAL VACCINES; CHICKENS; DENDRITIC CELLS; GALACTOSYLTRANSFERASES; HUMANS; INJECTIONS, SUBCUTANEOUS; LIPOSOMES; LYMPH NODES; LYMPHOCYTE ACTIVATION; MICE; OVALBUMIN; PEPTIDE FRAGMENTS; RABBITS;

EID: 67349093586     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.03.019     Document Type: Article

References (51)

1. Zinkernagel R.M., Ehl S., Aichele P., Oehen S., Kundig T., and Hengartner H. Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity. Immunol Rev 156 (1997) 199-209
2. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 (1998) 245-252
3. Ravetch J.V., and Clynes R.A. Divergent roles for Fc receptors and complement in vivo. Annu Rev Immunol 16 (1998) 421-432
4. + CTL responses in vivo. J Immunol 168 (2002) 2240-2246
5. Regnault A., Lankar D., Lacabanne V., Rodriguez A., Thery C., Rescigno M., et al. Fcγ receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med 189 (1999) 371-380
6. Machy P., Serre K., and Leserman L. Class I-restricted presentation of exogenous antigen acquired by Fcγ receptor-mediated endocytosis is regulated in dendritic cells. Eur J Immunol 30 (2000) 848-857
7. Stoner R.D., and Terres G. Enhanced antitoxin responses in irradiated mice elicited by complexes of tetanus toxoid and specific antibody. J Immunol 91 (1963) 761-770
8. Manca F., Fenoglio D., LiPira G., Kunkl A., and Celada F. Effect of antigen/antibody ratio on macrophage uptake, processing and presentation to T cells of antigen complexed with polyclonal antibodies. J Exp Med 173 (1991) 37-48
9. Gosselin E.J., Wardwell K., Gosselin D.R., Alter N., Fisher J.L., and Guyre P.M. Enhanced antigen presentation using human Fc gamma receptor (monocyte/macrophage)-specific immunogens. J Immunol 149 (1992) 3477-3481
10. Celis E., and Chang T.W. Antibodies to hepatitis B surface antigen potentiate the response of human T lymphocyte clones to the same antigen. Science 224 (1984) 297-299
11. Houston W.E., Kremer R.J., Crabbs C.L., and Spertzel R.O. Inactivated Venezuelan equine encephalomyelitis virus vaccine complexed with specific antibody: enhanced primary immune response and altered pattern of antibody class elicited. J Infect Dis 135 (1977) 600-610
12. Villinger F., Mayne A.E., Bostik P., Mori K., Jensen P.E., Ahmed R., et al. Evidence for antibody-mediated enhancement of simian immunodeficiency virus (SIV) Gag antigen processing and cross presentation in SIV-infected rhesus macaques. J Virol 77 (2003) 10-24
13. Stager S., Alexander J., and Kirby A.C. Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8(+) T-cell responses. Nat Med 9 (2003) 1287-1292
14. Siegrist C.A. Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants. Vaccine 21 (2003) 3406-3412
15. Galili U., Rachmilewitz E.A., Peleg A., and Flechner I. A unique natural human IgG antibody with anti-α-galactosyl specificity. J Exp Med 160 (1984) 1519-1531
16. Galili U., Macher B.A., Buehler J., and Shohet S.B. Human natural anti-α-galactosyl IgG. II. The specific recognition of α(1 → 3)-linked galactose residues. J Exp Med 162 (1985) 573-582
17. Galili U., Clark M.R., Shohet S.B., Buehler J., and Macher B.A. Evolutionary relationship between the anti-Gal antibody and the Galα1 → 3Gal epitope in primates. Proc Natl Acad Sci USA 84 (1985) 1369-1373
18. Galili U. Evolution and pathophysiology of the human natural anti-Gal antibody. Springer Semin Immunopathol 15 (1993) 155-171
19. Galili U., Buehler J., Shohet S.B., and Macher B.A. The human natural anti-Gal IgG. III. The subtlety of immune tolerance in man as demonstrated by crossreactivity between natural anti-Gal and anti-B antibodies. J Exp Med 165 (1987) 693-704
20. Barral D.C., and Brenner M.B. CD1 antigen presentation: how it works. Nat Rev Immunol 7 (2007) 929-941
21. Galili U., Mandrell R., Hamadeh R.M., Shohet S.B., and Griffis J.M. Interaction between human natural anti-α-galactosyl immunoglobulin G and bacteria of the human flora. Infect Immun 56 (1988) 1730-1737
22. Galili U., Anaraki F., Thall A., Hill-Black C., and Radic M. One percent of human circulating B lymphocytes are capable of producing the natural anti-Gal antibody. Blood 82 (1993) 2485-2493
23. Galili U., Shohet S.B., Kobrin E., Stults C.L.M., and Macher B.A. Man, apes, and Old World monkeys differ from other mammals in the expression of α-galactosyl epitopes on nucleated cells. J Biol Chem 263 (1988) 17755-17762
24. Galili U. Interaction of the natural anti-Gal antibody with α-galactosyl epitopes: a major obstacle for xenotransplantation in humans. Immunol Today 14 (1993) 480-482
25. Good A.H., Cooper D.K., Malcolm A.J., Ippolito R.M., Koren E., Neethling F.A., et al. Identification of carbohydrate structures which bind human anti-porcine antibodies: implication for discordant xenografting in man. Transplant Proc 24 (1992) 559-562
26. Sandrin M., Vaughan H.A., Dabkowski P.L., and McKenzie I.F.C. Anti-pig IgM antibodies in human serum react predominantly with Galα1-3Gal epitopes. Proc Natl Acad Sci USA 90 (1993) 11391-11395
27. Collins B.H., Cotterell A.H., McCurry K.R., Alvarado C.G., Magee J.C., Parker W., et al. Cardiac xenografts between primate species provide evidence of the α-galactosyl determinant in hyperacute rejection. J Immunol 154 (1995) 5500-5510
28. Manches O., Plumas J., Lui L., Chaperot L., Molens J.P., Sotto J.J., et al. Anti-Gal mediated targeting of human B lymphoma cells to antigen-presenting cells: a potential method for immunotherapy with autologous tumor cells. Haematologica 90 (2005) 625-634
29. Abdel-Motal U., Wang S., Lu S., Wigglesworth K., and Galili U. Increased immunogenicity of HIV gp120 engineered to express Galα1-3Galβ1-4GlcNac-R epitopes. J Virol 80 (2006) 6943-6951
30. Abdel-Motal U.M., Guay H.M., Wigglesworth K., Welsh R.M., and Galili U. Increased immunogenicity of influenza virus vaccine by anti-Gal mediated targeting to antigen presenting cells. J Virol 81 (2007) 9131-9141
31. Benatuil L., Kaye J., Rich R.F., Fishman J.A., Green W.R., and Iacomini J. The influence of natural antibody specificity on antigen immunogenicity. Eur J Immunol 35 (2005) 2638-2647
32. Thall A.D., Maly P., and Lowe J.B. Oocyte Galα1-3Gal epitopes implicated in sperm adhesion to the zona pellucida glycoprotein ZP3 are not required for fertilization in the mouse. J Biol Chem 270 (1995) 21437-21442
33. Karttunen J., Sanderson S., and Shastri N. Detection of rare antigen-presenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens. Proc Natl Acad Sci USA 89 (1992) 6020-6024
34. Lugade A.A., Moran J.P., Gerber S.A., Rose R.C., Frelinger J.G., and Lord E.M. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol 174 (2005) 7516-7523
35. Galili U., Wigglesworth K., and Abdel-Motal U.M. Intratumoral injection of α-gal glycolipids induces xenograft-like destruction and conversion of lesions into endogenous vaccines. J Immunol 178 (2007) 4676-4687
36. Galili U. Immune response, accommodation and tolerance to transplantation carbohydrate antigens. Transplantation 78 (2004) 1093-1098
37. Sanderson S., and Shastri N. LacZ inducible, antigen/MHC-specific T cell hybrids. Int Immunol 6 (1994) 369-376
38. Bottrel R.L., Dutra W.O., Martins F.A., Gontijo B., Carvalho E., Barral-Netto M., et al. Flow cytometric determination of cellular sources and frequencies of key cytokine-producing lymphocytes directed against recombinant LACK and soluble Leishmania antigen in human cutaneous leishmaniasis. Infect Immun 69 (2001) 3232-3239
39. Dhodapkar K.M., Krasovsky J., Williamson B., and Dhodapkar M.V. Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med 195 (2002) 125-133
40. Groh V., Li Y.Q., Cioca D., Hunder N.N., Wang W., Riddell S.R., et al. Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells. Proc Natl Acad Sci USA 102 (2005) 6461-6466
41. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y.J., et al. Immunobiology of dendritic cells. Annu Rev Immunol 18 (2000) 767-811
42. LaTemple D.C., Abrams J.T., Zhang S.Y., and Galili U. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for α1,3galactosyltransferase. Cancer Res 59 (1999) 3417-3423
43. Deriy L., Ogawa H., Gao G.P., and Galili U. In vivo targeting of vaccinating tumor cells to antigen-presenting cells by a gene therapy method with adenovirus containing the α1,3galactosyltransferase gene. Cancer Gene Ther 12 (2005) 528-539
44. Rossi G.R., Mautino M.R., Unfer R.C., Seregina T.M., Vahanian N., and Link C.J. Effective treatment of preexisting melanoma with whole cell vaccines expressing α(1,3)-galactosyl epitopes. Cancer Res 65 (2005) 10555-10561
45. Guyre P.M., Graziano R.F., Goldstein J., Wallace P.K., Morganelli P.M., Wardwell K., et al. Increased potency of Fc-receptor-targeted antigens. Cancer Immunol Immunother 45 (1997) 146-148
46. Sturmhoefel K., Lee K., Gray G.S., Thomas J., Zollner R., O'Toole M., et al. Potent activity of soluble B7-IgG fusion proteins in therapy of established tumors and as vaccine adjuvant. Cancer Res 59 (1999) 4964-4972
47. Repik P.M., Strizki J.M., and Galili U. Differential host dependent expression of α-galactosyl epitopes on viral glycoproteins: a study of Eastern equine encephalitis virus as a model. J Gen Virol 75 (1994) 1177-1181
48. Galili U., Repik P.K., Anaraki F., Mozdzanowska K., Washko G., and Gerhard W. Enhancement of antigen presentation of influenza virus hemagglutinin by the natural anti-Gal antibody. Vaccine 14 (1996) 321-328
49. Smith D.F., Larsen R.D., Mattox S., Lowe J.B., and Cummings R.D. Transfer and expression of a murine UDP-Gal:beta-D-Gal-alpha 1,3-galactosyltransferase gene in transfected Chinese hamster ovary cells. Competition reactions between the α1,3-galactosyltransferase and the endogenous α2,3-sialyltransferase. J Biol Chem 265 (1990) 6225-6234
50. Hamilton S.R., Bobrowicz P., Bobrowicz B., Davidson R.C., Li H., Mitchell T., et al. Production of complex human glycoproteins in yeast. Science 301 (2003) 1244-1246
51. Henion T.R., Gerhard W., Anaraki F., and Galili U. Synthesis of α-gal epitopes on influenza virus vaccines by recombinant α1,3galactosyltransferase enables the formation of immune complexes with the natural anti-Gal antibody. Vaccine 15 (1997) 1174-1182